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Abstract
Background: Obesity seems to be linked to the hypothalamic involvement in craniopharyngioma. We
evaluated the pre-surgery relationship between the degree of this involvement on magnetic resonance
imaging and insulin resistance, as evaluated by the homeostasis model insulin resistance index (HOMA).
As insulin-like growth factor 1, leptin, soluble leptin receptor (sOB-R) and ghrelin may also be involved,
we compared their plasma concentrations and their link to weight change.
Methods: 27 children with craniopharyngioma were classified as either grade 0 (n = 7, no hypothalamic
involvement), grade 1 (n = 8, compression without involvement), or grade 2 (n = 12, severe involvement).
Results: Despite having similar body mass indexes (BMI), the grade 2 patients had higher glucose, insulin
and HOMA before surgery than the grade 0 (P = 0.02, <0.05 and 0.02 respectively) and 1 patients (P <
0.02 and <0.03 for both insulin and HOMA). The grade 0 (5.8 ± 4.9) and 1 (7.2 ± 5.3) patients gained
significantly less weight (kg) during the year after surgery than did the grade 2 (16.3 ± 7.4) patients. The
pre-surgery HOMA was positively correlated with these weight changes (P < 0.03).
The data for the whole population before and 6–18 months after surgery showed increases in BMI (P <
0.0001), insulin (P < 0.005), and leptin (P = 0.0005), and decreases in sOB-R (P < 0.04) and ghrelin (P <
0.03).
Conclusion:  The hypothalamic involvement by the craniopharyngioma before surgery seems to
determine the degree of insulin resistance, regardless of the BMI. The pre-surgery HOMA values were
correlated with the post-surgery weight gain. This suggests that obesity should be prevented by reducing
inn secretion in those cases with hypothalamic involvement.
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Background
Obesity is a major problem in some children with hypoth-
alamic-pituitary lesions. The risk factors for obesity in
children surviving brain tumors are the hypothalamic
location, tumor histology, particularly craniopharyngi-
oma and pilocytic astrocytoma, and the extent of surgery
[1]. Long-term survivors of childhood cancer are at
increased risk of suffering from metabolic syndrome [2,3]
and nonalcoholic fatty liver disease [4]. There is, pres-
ently, no effective long-term treatment [5,6].
The exact cause of this obesity is unclear. Lesions of the
ventromedial hypothalamus produce obesity and hyper-
insulinemia in rats [7], while complete vagotomy reverses
the obesity and lowers plasma insulin [8]. Two explana-
tions have been advanced. One postulates that the dam-
age leads to hyperphagia and obesity via a direct neural
mechanism involving the central appetite centers and that
the hyperinsulinemia is secondary to the obesity. The
other postulates that the damage causes disinhibition of
vagal tone at the pancreatic β-cells, which leads to insulin
hypersecretion and obesity.
There is a link between the degree of hypothalamic
involvement evaluated by magnetic resonance imaging
(MRI) and the weight of a child before and after surgery to
remove the craniopharyngioma [9-12], but exactly how
this leads to obesity is unknown. The destruction or func-
tional impairment of the hypothalamus is probably
responsible for the failure to integrate neuronal, hormo-
nal and metabolic signals from the body, leading to
changed feeding behavior. Insulin-like growth factor
(IGF) 1, insulin, leptin and ghrelin may all be involved.
We have shown that the pre-surgery plasma fasting insulin
concentrations of children with craniopharyngioma are
positively correlated with the weight change (kg) during
the year after surgery [13]. Others [14,15] have suggested
that the higher-than-expected plasma leptin concentra-
tion for the body mass index (BMI) indicates a disturbed
feedback control of leptin secretion due to the craniophar-
yngioma and/or surgery. The fasting plasma ghrelin con-
centrations of adults [16] and children [17] operated on
for craniopharyngioma are not different from those of
obese controls. Both authors suggest that an elevated fast-
ing ghrelin is unlikely to be responsible for the obesity
that occurs after hypothalamic damage.
Objective
To evaluate the pre-surgery relationship between the
degree of hypothalamic involvement by a craniopharyngi-
oma, determined by MRI, and the insulin resistance, eval-
uated by the homeostasis model insulin resistance index
(HOMA), in a population of prepubertal children. We
also measured the plasma concentrations of IGF-1, leptin,
soluble leptin receptor (sOB-R) and ghrelin, before and
6–18 months after surgery, when the blood sample was
large enough. We compared these plasma concentrations
between them and to the changes in body weight.
Methods
Patients
A series of 27 patients (15 boys) were selected consecu-
tively from a cohort of craniopharyngiomas operated on
at the Hôpital Necker-Enfants Malades. The selection cri-
teria were a complete surgical history at the same depart-
ment, follow-up performed by the same pediatric
endocrinologist (R Brauner) and the availability of at least
one pre-surgery plasma sample.
The pre-surgery neuroradiological data were reviewed ret-
rospectively by one author (C Sainte-Rose) blinded to the
clinical data. The relationship between the hypothalamus
and the craniopharyngioma was used to assign patients to
a grade: grade 0 included those without hypothalamic
involvement (n = 7); grade 1 included those who had an
identifiable hypothalamus that was compressed and dis-
placed by a suprasellar or intraventricular tumor (n = 8);
and grade 2 included those who had severe hypothalamic
involvement (n = 12) [10].
All the patients were aged 8.3 ± 3.5 (2.8–15.7) years at the
first evaluation before surgery and were followed for at
least one year after surgery.
Protocol
Informed consent for the evaluations and treatments was
obtained from the children's parents. The Ethical Review
Committee (Comité de Protection des Personnes Ile de
France III) stated that "this research was found to conform
to generally accepted scientific principles and research
ethical standards and to be in conformity with the laws
and regulations of the country in which the research
experiment was performed".
The endocrine status of each patient was evaluated at 8:00
a.m in a fasting state both before surgery and after surgical
resection of craniopharyngioma, when the patients were
on replacement thyroxin, hydrocortisone and desmos-
pressin. Before surgery, 81% of the patients lacked growth
hormone (GH), 37% lacked thyroid stimulating hor-
mone, 22% lacked adrenocorticotropin hormone, and
7% lacked vasopressin. The frequency of deficiencies did
not vary with the degree of hypothalamic involvement.
Replacement thyroxin and hydrocortisone were always
initiated the day before surgery; the plasma cortisol con-
centrations of the patients with normal plasma cortisol
concentrations before surgery were measured at 8:00 a.m.
after surgery, 12 hours after the last dose of hydrocorti-
sone just before leaving the hospital. All, except one, had
GH, thyroid stimulating hormone, adrenocorticotropinBMC Pediatrics 2009, 9:24 http://www.biomedcentral.com/1471-2431/9/24
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hormone and vasopressin deficiencies after surgery. At the
last clinical evaluation, five were of prepubertal age, two
had spontaneous pubertal development and the 20 others
had complete gonadotropin deficiency.
The fasting plasma concentrations of at least one of insu-
lin, leptin, sOB-R, and ghrelin and calculation of HOMA
and free leptin index (FLI) were measured before surgery.
The interval between surgery and the second evaluation of
these concentrations was 6 to 18 months, depending on
sample availability. All patients remained prepubertal and
none of them was given GH or sex steroids during the
study period.
Methods
The endocrine evaluation included the response to a GH
stimulation test, the fasting plasma concentrations of glu-
cose, insulin, IGF-1, free thyroxin, cortisol, and concomi-
tant plasma and urinary osmolalities. These parameters
were also evaluated after surgery.
The GH secretion was first assessed by the sequential
arginine-insulin test and then by the ornithin test. The
insulin test was not performed in patients in a critical
medical state. GH deficiency was defined by a GH peak of
less than 10 μg/L. The hypothalamic-pituitary-thyroid axis
was assessed by measuring plasma free thyroxin concen-
trations, and any deficiency (< 12 pmol/L) was treated
with thyroxin (75–100 μg/m2/day). The hypothalamic-
pituitary-adrenal axis was assessed by measuring the
plasma cortisol concentration at 8:00 a.m., and any defi-
ciency (<80 μg/L) was treated with hydrocortisone (10–15
mg/m2/day). Central diabetes insipidus was treated with
desmopressin, given orally or intranasally twice daily at a
dose that kept the urine volume normal. The replacement
doses did not vary with the degree of hypothalamic
involvement.
Leptin and its sOB-R (both assessed with kits from Diag-
nostic Systems Laboratories, Inc., Webster, TX) and total
ghrelin (RIA from Linco Research, St. Charles, MO) were
measured on plasma samples obtained from fasting
patients and stored at -20°C. All samples assayed for a
given biological parameter were included in the same run.
The detection limits of the assays were 0.10 μg/L for lep-
tin, 0.14 μg/L for sOB-R, and 93 ng/L for ghrelin. Within-
run coefficients of variation were less than 5% for leptin,
13% for sOB-R, and 10% for ghrelin. The sOB-R assay was
not affected by adding up to 300 μg/L recombinant leptin
to plasma samples. The FLI was determined by calculating
the ratio between the concentrations of leptin and sOB-R,
multiplied by 100. The HOMA was calculated as
described in [18].
Height is expressed as SDS scores for chronological age
[19], BMI as kg/m2 and z-score (zs) [20], and IGF-1 as zs
[21].
Data are means ± SD. The groups were compared with the
Mann-Whitney U-test. The data before surgery were com-
pared to those after surgery with the Wilcoxon signed-
rank tests. Correlations were analyzed using the Spearman
test.
Results
1. Comparison of the groups
Despite having similar ages and BMIs, the grade 2 patients
had higher glucose, insulin plasma concentrations and
HOMA before surgery than did the grades 0 and 1 patients
(Table 1). The grade 0 and 1 patients gained significantly
less weight (kg) during the year after surgery than did the
Table 1: Craniopharyngioma before surgery
Hypothalamic involvement
Grade 01 2 0 vs 1 0 vs 2 1 vs 2
PPP
Age, years 6.5 ± 4.3 (7) 8.1 ± 2.8 (8) 9.4 ± 3.1 (12)
Height, SDS 0.46 ± 1.8 (7) -1.1 ± 1.1 (8) -0.57 ± 1.1 (12) <0.04
BMI, zs 0.20 ± 2.0 (7) 0.58 ± 1.9 (8) 1.5 ± 1.3 (12)
Glucose, mmol/L 4.4 ± O.25 (5) 4.3 ± 0.6 (7) 5.1 ± 0.6 (10) 0.02 <0.02
Insulin, mIU/L 5.1 ± 2.4 (7) 5.4 ± 3.3 (8) 12.0 ± 11.8 (11) <0.05 <0.03
HOMA 1.31 ± 0.6 (5) 1.28 ± 0.9 (7) 3.65 ± 3.5 (9) 0.02 <0.03
IGF-1, zs -2.8 ± 1.7 (7) -3.0 ± 3.1 (8) -2.1 ± 2.2 (12) <0.03
Leptin, μg/L 5.6 ± 2.6 (5) 7.2 ± 4.5 (8) 14.0 ± 9.8 (12)
sOB-R, μg/L 72 ± 37 (2) 70 ± 35 (8) 50 ± 27 (7)
Free leptin index 12.7 ± 13 (2) 12.4 ± 9.O (8) 34 ± 33 (7)
Ghrelin, ng/L 2256 ± 331 (2) 1091 ± 251 (5) 1083 ± 222 (6) 0.05 <0.05
mean ± SD
Number in parentheses indicate the effectivesBMC Pediatrics 2009, 9:24 http://www.biomedcentral.com/1471-2431/9/24
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grade 2 patients (Table 2). The pre-surgery HOMA was
positively correlated with these weight changes (P < 0.03).
Before surgery, the plasma IGF-1 concentrations were
lower in grade 1 than in grade 2 patients, and those of
ghrelin were greater in grade 0 than in grade 1 and 2
patients. After surgery, the plasma concentrations were
lower in grade 0 than in grade 2 for IGF-1, and in grade 1
than in grade 2 for insulin and leptin.
2. Comparison of the variables in the whole population
The data for the whole population before and 6–18
months after surgery showed increases in BMI (P <
0.0001), insulin (P < 0.005), leptin (P = 0.0005), FLI (P <
0.008), and decreases in sOB-R (P < 0.04) and ghrelin (P
< 0.03). The comparison of leptin with BMI before and
after surgery according to the hypothalamic involvement
is shown on Figure 1.
The BMIs before and after surgery were positively corre-
lated with the HOMA and with the plasma concentrations
of insulin and leptin, as were the insulin values with IGF-
1 (Table 3).
After surgery, the plasma concentrations of leptin were
positively correlated with those of insulin and IGF-1. The
plasma concentrations of ghrelin were negatively corre-
lated with those of insulin, IGF-1 and leptin.
When the data before and after surgery were analysed
together, the leptin concentrations were negatively corre-
lated with those of sOB-R.
Discussion
Our main finding is that the hypothalamic involvement
by the craniopharyngioma before surgery seems to deter-
mine the degree of insulin resistance evaluated by the
HOMA, regardless of the BMI. In turn, the pre-surgery
HOMA values were correlated with the post-surgery
weight gain.
1. Hypothalamic involvement
We find that a greater hypothalamic involvement before
surgery, as evaluated by MRI, is associated with signifi-
cantly higher glucose and insulin plasma concentrations
and HOMA, and a lower concentration of ghrelin. There
was no significant association between the BMI and the
degree of hypothalamic involvement in the whole popu-
lation or in the 21/27 patients for whom the HOMA was
available. This suggests that the insulin resistance before
surgery was mainly due to the hypothalamic damage
caused by the craniopharyngioma. One grade 2 patient
with a high HOMA before surgery (2.93) developed dia-
betes at 22.4 years, with high fasting plasma insulin con-
centrations (27 mIU/L); treatment with Metformine and
Glimepiride normalised the blood glucose concentration.
The changes in weight during the year after surgery dif-
fered according to the hypothalamic involvement. The
positive correlation between the HOMA before surgery
and these changes suggests that the insulin resistance
induced by the craniopharyngioma itself influences the
body weight after surgery.
De Vile et al [9] used MRI to classify the hypothalamic
involvement in children with craniopharyngioma 1.2–
19.2 years after surgery. They showed that the 10/17
Table 2: Craniopharyngioma 1 year after surgery
Hypothalamic involvement
Grade 01 2 0 vs 1 0 vs 2 1 vs 2
PPP
Height, SDS 0.13 ± 1.3 (7) -1.6 ± 1.1 (8) -0.55 ± 1.3 (12) <0.04
BMI, zs 2.7 ± 1.1 (7) 2.5 ± 1.8 (8) 4.0 ± 1.3 (12) <0.05
Changes in weight, Kg 5.8 ± 4.9 (7) 7.2 ± 5.3 (8) 16.3 ± 7.4 (12) <0.007 <0.02
Changes in weight, SDS 1.0 ± 1.2 (7) 1.2 ± 0.9 (8) 2.5 ± 1.4 (12) <0.05 <0.04
Glucose, mmol/L NA 3.9 ± 1.2 (2) 4.6 ± 0.7 (7)
Insulin, mIU/L 10.1 ± 9.0 (2) 6.1 ± 3.7 (5) 47 ± 58 (10) <0.04
HOMA NA 0.9 ± 0.3 (2) 7.1 ± 9.0 (7)
IGF-1, zs -4.3 ± 0.6 (2) -2.8 ± 2.0 (6) -2.4 ± 0.8 (10) <0.05
Leptin, μg/L 14.2 ± 14 (2) 32 ± 14 (4) 61 ± 26 (10) <0.04
sOB-R, μg/L NA 30 ± 5.3 (4) 28 ± 7.2 (5)
Free leptin index NA 113 ± 63 (4) 279 ± 102 (5) 0.05
Ghrelin, ng/L NA 994 ± 263 (4) 722 ± 126 (6)
mean ± SD; NA: not available.
Number in parentheses indicate the effectives
The biological data were collected 6–18 months after surgeryBMC Pediatrics 2009, 9:24 http://www.biomedcentral.com/1471-2431/9/24
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patients with the greatest involvement had a history of
extreme weight loss or weight gain at presentation, and a
significantly greater increase in BMI at follow-up than
those who had no, or intermediate hypothalamic involve-
ment. Müller et al [11,12] showed that hypothalamic
involvement and a familial disposition to obesity seem to
have a major impact on the development of obesity,
whereas endocrine deficiencies and hormone replace-
ment therapy do not.
2. Mechanism of the obesity
It has been suggested that the craniopharyngioma and/or
surgery disturb the feedback control of leptin secretion.
Brabant et al [14] found that the plasma leptin concentra-
tions of patients with a pituitary adenoma were compara-
ble to those of controls, whereas 7/18 patients with
craniopharyngioma had higher than expected leptin con-
centrations for their BMI. This was also reported for 11
patients with a suprasellar craniopharyngioma, whereas 3
patients with intrasellar craniopharyngioma had lower,
almost normal leptin concentrations [15]. In contrast,
Srinivasan et al [22] reported equally high leptin concen-
trations in children after removal of the craniopharyngi-
oma and in controls matched for their BMI. They also
found no difference in total body fat or in the reduction
in insulin sensitivity. We [23] have shown that the obesity
that follows cachexia after the treatment of hypothalamic
tumors in children younger than one year old is not due
to dysregulation of leptin secretion, and that the leptin
concentrations and sOB-R remain regulated by factors like
testosterone. The sOB-R decreased in all but one patient
from before to after surgery. This decrease was significant
and concomitant with the increases in BMI and leptin.
The sOB-R concentrations were negatively correlated with
the BMI and the leptin concentrations when the data
before and after surgery were analysed together. This sug-
gests that the relationship between leptin and its receptor
is not altered by the surgery.
Goldstone et al [16] showed that the fasting plasma ghre-
lin concentrations of adults operated on for craniophar-
yngioma were negatively correlated with the percent of
body fat, plasma insulin and HOMA. We find that the
plasma ghrelin concentrations before surgery are not cor-
related with the other variables. They decreased signifi-
cantly after surgery to become closely and negatively
correlated with the concentrations of insulin (with a cor-
relation coefficient similar to that found by Goldstone),
IGF-1 and leptin.
The plasma IGF-1 concentrations were positively corre-
lated with insulin before surgery, and with BMI, insulin
and leptin after surgery. They were greater in the group
with hypothalamic involvement than in the group with-
Comparison of leptin with BMI (kg/m2) before (n = 25) and after (n = 16) surgery for craniopharyngioma according to the  hypothalamic involvement Figure 1
Comparison of leptin with BMI (kg/m2) before (n = 25) and after (n = 16) surgery for craniopharyngioma 
according to the hypothalamic involvement.
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out such involvement. They were over -2 zs in 3/26
patients, despite the complete GH deficiency. This sug-
gests that insulin stimulates IGF-1 production, and may
explain the normal growth rate of these patients despite
their GH deficiency.
3. Forces, limitations and medical implications
All patients had craniopharyngioma and were evaluated
before and after surgery. The second evaluation was per-
formed before GH or sex steroid treatment was started.
They were all operated on in the same department and fol-
lowed by the same endocrinologist. But not all the param-
eters were assayed in each sample.
There is, presently, no effective long-term treatment for
these patients. Lustig et al [5,6] treated patients with
hypothalamic obesity with somatostatin agonist. This
promoted weight loss, which was correlated with a reduc-
tion in insulin secretion on oral glucose tolerance testing
and in leptin concentrations. Srinivasan et al [22] found
no differences in the metabolic parameters and body
compositions of 5 craniopharyngioma cases treated with
GH and 10 untreated cases. Geffner et al [24] showed that
treating children with craniopharyngioma with GH for 3
years did not modulate the weight gain. Mason et al [25]
treated with dextroamphetamine 5 patients with signifi-
cant weight gain and poor attention following surgical
treatment of craniopharyngioma, and found an improve-
ment. Alemzadeh et al [26] found that diazoxide (2 mg/
kg/day in 3 doses p.o.) decreased the weight and plasma
insulin of obese hyperinsulinemic adults.
Conclusion
The degree of hypothalamic involvement determines the
insulin secretion, and possibly that of ghrelin, which
determine the BMI and its evolution; this, in turn deter-
mines the leptin concentration. Thus, obesity should be
prevented by reducing insulin secretion in those cases
with hypothalamic involvement.
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